---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-26-000020"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T01:34:25.560261+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q1 revenue falls 9% YoY to $20.6M; net loss $13.7M

## Summary
- Worldwide revenue $20.6M (-9% YoY, -12% constant currency); U.S. $13.3M (-7%), international $7.3M (-12%).
- Ex-China international revenue grew 22% YoY; China sales paused awaiting registration renewal.
- Gross margin improved to 78% (vs 73% Q1 2025); total op. expenses $29.0M (-6% YoY).
- Adjusted EBITDA loss $8.5M; net loss $13.7M ($0.33 per share) vs $14.4M ($0.36) a year ago.
- FY 2026 outlook reaffirmed: revenue $90-92M, gross margin ~75%, opex $113-115M, cash burn ~$23M.

## SEC filing metadata
- accession: 0001127537-26-000020
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000020/0001127537-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000020/lung-20260429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-26-000020
- JSON: https://secwatch.observer/filing/0001127537-26-000020.json
- Plain text: https://secwatch.observer/filing/0001127537-26-000020.txt

## Key facts
- Earnings Releases
  Pulmonx Corp reported the first quarter of 2026 ended March 31, 2026 results: revenue $20.6 million, net income Net loss in the first quarter of 2026 was $13.7 million, EPS $0.33 per share. Guidance reaffirmed.
  - Period: the first quarter of 2026 ended March 31, 2026
  - Revenue: $20.6 million
  - Net income: Net loss in the first quarter of 2026 was $13.7 million
  - EPS: $0.33 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. Recent Highlights • Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basis • Delivered $13.3 million in U.S. revenue in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753726000020/0001127537-26-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.